<DOC>
	<DOCNO>NCT02227875</DOCNO>
	<brief_summary>To test whether Mylan 's insulin glargine daily non-inferior Lantus® daily ( administer combination anti-diabetic drug ) base change HbA1c baseline 24 week</brief_summary>
	<brief_title>Non-inferiority Study Compare Efficacy Safety Mylan 's Insulin Glargine With Lantus® Type 2 Diabetes Mellitus Patients ( INSTRIDE 2 )</brief_title>
	<detailed_description>This trial multi-center , open-label , randomize , parallel group trial patient T2DM compare efficacy safety Mylan 's insulin glargine Lantus® . Patients establish diagnosis T2DM per ADA 2014 criterion satisfy selection criterion include trial . This follow 24-week randomized , comparative , parallel-assignment treatment period Mylan 's insulin glargine Lantus® ( addition anti-diabetic drug ) . After treatment period , follow-up visit ; 4 week patient put back approved medication .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients establish diagnosis T2DM per ADA 2014 criterion also fulfill follow : Diagnosis establish 1 year prior screen Insulinnaïve OR On Lantus® daily stable dose ( ±15 % variation dose ) least 3 month prior screen Body mass index ( BMI ) 18.50 40.00 kg/m2 screening ( value inclusive ) . Stable weight , 5 kg gain loss , 3 month prior screen ; information collect patient interview medical history . Hemoglobin ≥9.0 g/dL screen Glycosylated hemoglobin ( HbA1c ) &lt; 10.5 % 7.5 10.5 % insulin naïve patient screen . History hypersensitivity active inactive ingredient insulin/insulin analog preparation use trial , OR history significant allergic drug reaction . History use animal insulin within last 3 year , insulin Lantus® within last 3 month prior screen , use biosimilar insulin glargine time prior screening . Patients require basalbolus insulin therapy opinion investigator require mealtime insulin order achieve glycemic control . Regular use immunemodulator therapy 1 year prior screen . History ≥2 episodes severe hypoglycemia within 6 month screen history hypoglycemia unawareness ( sample questionnaire provide Appendix I ) judge investigator . History ≥1 episode hyperglycemic hyperosmolar coma emergency room visit uncontrolled diabetes lead hospitalization within 6 month prior screen . Serological evidence human immunodeficiency virus ( HIV ) , hepatitis B ( HbSAg ) hepatitis C ( HCVAb ) antibodies screen . History drug alcohol dependence abuse 1 year prior screen . Receipt another investigational drug 3 month prior screen ( per local regulation ) , screen visit within 5 halflives another investigational drug ( whichever longer ) , schedule receive another investigational drug current trial period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>